[go: up one dir, main page]

WO2001042205A3 - Treatment of inflammatory bowel disease with vitamin d compounds - Google Patents

Treatment of inflammatory bowel disease with vitamin d compounds Download PDF

Info

Publication number
WO2001042205A3
WO2001042205A3 PCT/US2000/042393 US0042393W WO0142205A3 WO 2001042205 A3 WO2001042205 A3 WO 2001042205A3 US 0042393 W US0042393 W US 0042393W WO 0142205 A3 WO0142205 A3 WO 0142205A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
inflammatory bowel
bowel disease
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/042393
Other languages
French (fr)
Other versions
WO2001042205A2 (en
Inventor
Margherita T Cantorna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Priority to EP00992552A priority Critical patent/EP1233942A2/en
Priority to AU45100/01A priority patent/AU4510001A/en
Priority to CA002390859A priority patent/CA2390859A1/en
Priority to JP2001543506A priority patent/JP2003516386A/en
Publication of WO2001042205A2 publication Critical patent/WO2001042205A2/en
Publication of WO2001042205A3 publication Critical patent/WO2001042205A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a vitamin D compound in an amount effective to treat the disease. The administration of a vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals.
PCT/US2000/042393 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds Ceased WO2001042205A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00992552A EP1233942A2 (en) 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds
AU45100/01A AU4510001A (en) 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds
CA002390859A CA2390859A1 (en) 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds
JP2001543506A JP2003516386A (en) 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin D compounds

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US16850199P 1999-12-02 1999-12-02
US60/168,501 1999-12-02
US19782700P 2000-04-14 2000-04-14
US60/197,827 2000-04-14
US20863200P 2000-06-01 2000-06-01
US60/208,632 2000-06-01
US23190600P 2000-09-11 2000-09-11
US60/231,906 2000-09-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/969,394 Continuation US20050070513A1 (en) 1999-12-02 2004-10-20 Treatment of inflammatory bowel disease with vitamin D compounds

Publications (2)

Publication Number Publication Date
WO2001042205A2 WO2001042205A2 (en) 2001-06-14
WO2001042205A3 true WO2001042205A3 (en) 2002-03-21

Family

ID=27496796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042393 Ceased WO2001042205A2 (en) 1999-12-02 2000-11-30 Treatment of inflammatory bowel disease with vitamin d compounds

Country Status (5)

Country Link
EP (1) EP1233942A2 (en)
JP (1) JP2003516386A (en)
AU (1) AU4510001A (en)
CA (1) CA2390859A1 (en)
WO (1) WO2001042205A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
JP6114292B2 (en) * 2011-10-21 2017-04-12 ウイスコンシン アラムニ リサーチ ファンデーション 2-Methylene-vitamin D analogs and their use
JP6397695B2 (en) * 2014-08-25 2018-09-26 学校法人自治医科大学 Anti-pylori agent
EP3331533B1 (en) * 2015-08-05 2021-09-01 Wisconsin Alumni Research Foundation Synthesis and biological activity of 2-methylene analogs of calcitriol and related compounds
US20220408780A1 (en) * 2020-02-11 2022-12-29 The E. Wolfson Medical Center A method effective for treating ulcerative colitis

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05294834A (en) * 1990-02-09 1993-11-09 Teijin Ltd Treating agent containing activated vitamin d
DE4405545A1 (en) * 1994-02-22 1995-08-31 Dietl Hans Oral vitamin compsn. with improved resorption
WO1996030326A1 (en) * 1995-03-30 1996-10-03 The Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
US5583125A (en) * 1992-10-06 1996-12-10 Schering Aktiengesellschaft 25-Carboxylic acid derivatives in the vitamin D series, process for their production, intermediate products for these processes, pharmaceutical preparations containing these derivatives as well as their use for the production of pharmaceutical agents
US5663157A (en) * 1992-06-30 1997-09-02 Schering Aktiengesellschaft 22-en-25-oxa derivatives in the vitamin D series, process for their production, pharmaceutical preparations containing these derivatives as well as their use as pharmaceutical agents
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
WO1998051664A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital 3-epi vitamin d2 compounds and uses thereof
WO1999003828A1 (en) * 1997-07-17 1999-01-28 F.Hoffmann-La Roche Ag Dihomo-seco-cholestanes with two unsaturated bones in the side chain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05294834A (en) * 1990-02-09 1993-11-09 Teijin Ltd Treating agent containing activated vitamin d
US5663157A (en) * 1992-06-30 1997-09-02 Schering Aktiengesellschaft 22-en-25-oxa derivatives in the vitamin D series, process for their production, pharmaceutical preparations containing these derivatives as well as their use as pharmaceutical agents
US5583125A (en) * 1992-10-06 1996-12-10 Schering Aktiengesellschaft 25-Carboxylic acid derivatives in the vitamin D series, process for their production, intermediate products for these processes, pharmaceutical preparations containing these derivatives as well as their use for the production of pharmaceutical agents
DE4405545A1 (en) * 1994-02-22 1995-08-31 Dietl Hans Oral vitamin compsn. with improved resorption
WO1996030326A1 (en) * 1995-03-30 1996-10-03 The Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
WO1998051664A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital 3-epi vitamin d2 compounds and uses thereof
WO1999003828A1 (en) * 1997-07-17 1999-01-28 F.Hoffmann-La Roche Ag Dihomo-seco-cholestanes with two unsaturated bones in the side chain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002167821 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 093 16 February 1994 (1994-02-16) *
See also references of EP1233942A2 *

Also Published As

Publication number Publication date
JP2003516386A (en) 2003-05-13
CA2390859A1 (en) 2001-06-14
WO2001042205A2 (en) 2001-06-14
AU4510001A (en) 2001-06-18
EP1233942A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2003072040A3 (en) Administration of agents for the treatment of inflammation
CA2289717A1 (en) Novel therapy for constipation
AU6915396A (en) Multiple sclerosis treatment
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
CA2117891A1 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
CA2290482A1 (en) Fructan containing composition for the prevention and treatment of colon cancer
ATE448788T1 (en) TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH 2-METHYLENE-19-NOR-VITAMIN D COMPOUNDS
HK1049105A1 (en) Method for administering a phosphodiesterase 4 inhibitor
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
HK1046089A1 (en) Therapeutic use of melatonin
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2000010590A3 (en) Cancer treatment
WO1998025594A3 (en) Lamotrigine in the treatment and prophylaxis of migraine
WO2002041841A3 (en) Compositions for adhesion prevention

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 543506

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2390859

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 45100/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000992552

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10148620

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000992552

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000992552

Country of ref document: EP